Skip to content

Asset turnover at other companies

Eli Lilly logo
Eli LillyLLY
0.7×+0.1×
Madrigal Pharmaceuticals, Inc. logo
Madrigal Pharmaceuticals, Inc.MDGL
+0.7×
Viking Therapeutics logo
Viking TherapeuticsVKTX
Theravance Biopharma logo
Theravance BiopharmaTBPH
0.3×+0.1×
Rigel Pharmaceuticals logo
Rigel PharmaceuticalsRIGL
0.9×-0.5×
Zevra Therapeutics, Inc. logo
Zevra Therapeutics, Inc.ZVRA
0.5×+0.3×

Other financials

Income statement

See full
Revenue$22.5M+2.1%
Gross profit$21.3M+0.6%
Operating income-$9.4M-512%
Net income-$8.7M-422%
EPS (diluted)-$0.10

Balance sheet

See full
Cash & equivalents$37.5M+149%
Total debt$823.0K-48.1%
Total equity$101.3M+48.7%
Total assets$162.0M+24.8%

Cash flow

See full
Operating cash flow$3.2M+2,565%
CapEx$178.0K+45.9%
Free cash flow$3.0M+1,296%

Valuation

See full
Market cap$694.58M-4.7%
Enterprise value$657.9M-8.0%
P/S5.9×-1.3×

Profitability

See full
Gross margin95.1%-1.1pp
Operating margin-0.1%-10.4pp
Net margin6.3%+3.3pp
FCF margin2.6%

Returns & leverage

See full
Return on equity8.2%+4.2pp
Debt / equity0.0×
Current ratio4.6×+1.0×

Where this comes from

Calculated from Gyre Therapeutics, Inc.’s reported figures.

Based on trailing twelve months.

The official record: Gyre Therapeutics, Inc.’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about Gyre Therapeutics, Inc.'s asset turnover.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Gyre Therapeutics, Inc.'s asset turnover?
Gyre Therapeutics, Inc. (GYRE) reported asset turnover of 0.8× in Q1 2026.
How has Gyre Therapeutics, Inc.'s asset turnover changed year-over-year?
Gyre Therapeutics, Inc.'s asset turnover increased by 0.4% year-over-year, from 0.8× to 0.8×.
What is the long-term trend for Gyre Therapeutics, Inc.'s asset turnover?
Over 4 years (2020 to 2025), Gyre Therapeutics, Inc.'s asset turnover has grown at a 38.6% compound annual growth rate (CAGR), from 0.2× to 0.8×.
What does asset turnover mean?
Trailing-twelve-month revenue divided by average total assets. Measures how many dollars of sales each dollar of assets generates — the efficiency leg of the DuPont decomposition of ROE.